This report from Life Science Intelligence provides the latest market data for the Global Atrial Septal Occlusion Devices Market. Information covered by this report includes:
· unit volumes & pricing forecast from 2019-2024
· analyses of the leading companies, and
· global market share analysis.
The global market for atrial septal occlusion devices is expected to reach an estimated $159.7 million in 2020 and is projected to grow at a CAGR (2020-2024) of 7%. Product segments covered by this report include transcatheter devices for atrial septal defect closure.
This report covers the impact of COVID-19 on the atrial septal occlusion devices market, including a recent forecast from 2020 to 2024. COVID-19 has also impacted leading competitors in the market, including Abbott and W.L. Gore. The report provides insights into trends, drivers, and limiters of the atrial septal occlusion devices market, as well as highlights potential opportunities.
Atrial septal defect (ASD) repair procedure volumes witnessed a major decline due to the COVID-19 pandemic. The decline in procedures was significant; however, procedure volumes are projected to rebound to pre-COVID-19 levels in early 2021.
Atrial septal defect is one of the most common congenital heart defects. The worldwide incidence of ASD is estimated at 56 per 100,000 live births and the prevalence is estimated at 1.6 per 1000 live births. Transcatheter atrial septal occlusion is considered to be a safe and effective approach for the percutaneous closure of ASD and has demonstrated long-term survival rates of more than 90%.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
